Characterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgrounds
Ma, Yixuan
1991-
VerfasserIn
aut
Junghanß, Christian
1969-
AkademischeR BetreuerIn
dgs
Sendler, Matthias
1980-
AkademischeR BetreuerIn
dgs
Jaster, Robert
1964-
AkademischeR BetreuerIn
dgs
Universität Rostock
Grad-verleihende Institution
dgg
Universitätsmedizin Rostock
Grad-verleihende Institution
dgg
text
theses
Text
Hochschulschrift
gw
2022
monographic
XA-DE
Rostock
Universität Rostock
publisher
26 September 2022
Rostock
Universitätsbibliothek Rostock
distributor
eng
application/pdf
1 Online-Ressource (106 Seiten) Illustrationen, Diagramme
Key proteins such as CK2, CDK, PI3K, AKT and KRAS are often considered as promising target molecules for therapeutic intervention strategies due to their important roles in the occurrence, development and prognosis of PDAC. The aim of this doctoral thesis was to explore the different effects of the above-mentioned key protein inhibitors on various PDAC cell lines, and to explore the effect of aberrations in the target genes of the inhibitors on the efficacy of the corresponding inhibitors by applying whole-exome sequencing (WES) and RNA sequencing (RNA-seq).<eng>
Open Access
Urheberrechtsschutz 1.0
vorgelegt von Yixuan Ma
Enthält Zeitschriftenartikel
The results of the dissertation presented here have been published in peer-reviewed journals with impact factor points. Work I: Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Krake, S.; Radefeldt, M.; Al-Ali, R.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4409. https://doi.org/10.3390/ijms23084409 Impact Factor 2022: 5.924; Work II: The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Sender, S.; Sekora, A.; Kong, W.; Bauer, P.; Ameziane, N.; Al-Ali, R.; Krake, S.; Radefeldt, M.; Weiss, F.U.; Lerch, M.M.; Parveen, A.; Zechner, D.; Junghanss, C.; Murua Escobar, H. Int. J. Mol. Sci. 2022, 23, 4295. https://doi.org/10.3390/ijms23084295 Impact Factor 2022: 5.924; Work III: Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines Ma, Y.; Schulz, B.; Trakooljul, N.; Al Ammar, M.; Sekora, A.; Sender, S.; Hadlich, F.; Zechner, D.; Weiss, F.U.; Lerch, M.M.; Jaster, R.; Junhanss, C.; Murua Escobar, H. Cancers 2022, 14, 4467. https://doi.org/10.3390/cancers14184467 Impact Factor 2022: 6.575
GutachterInnen: Christian Junghanß (Universitätsmedizin Rostock) ; Matthias Sendler (Universitätsmedizin Greifswald) ; Robert Jaster (Universitätsmedizin Rostock)
Dissertation Universität Rostock 2023 Kumulative Dissertation
610
616.994
610
44.87
44.81
44.48
http://purl.uni-rostock.de/rosdok/id00004330
https://doi.org/10.18453/rosdok_id00004330
https://nbn-resolving.org/urn:nbn:de:gbv:28-rosdok_id00004330-3
https://d-nb.info/1297582942/34
Characterization of pathway specific inhibitor response in pancreatic ductal adenocarcinoma in vitro models with different genetic backgrounds
Rostock : Universität Rostock, 2022
Druck-Ausgabe
(DE-627)1851556184
Ma, Yixuan, 1991 -
urn:nbn:de:gbv:28-rosdok_id00004330-3
10.18453/rosdok_id00004330
1389129488
rda
DE-627
230704
1851554688
20251226T211115.0
Converted from MARCXML to MODS version 3.8 using MARC21slim2MODS3-8_XSLT1-0.xsl
(Revision 1.174 20250328)
ger